• 1
    Frassetto L, Baluom M, Jacobsen W et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80: 1317.
  • 2
    Vogel M, Voigt E, Michaelis HC et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10: 939944.
  • 3
    Jain AK, Venkataramanan R, Shapiro R et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841845.
  • 4
    Guaraldi G, Cocchi S, Codeluppi M et al. Pharmacokinetic interaction between amprenavir/ritonavir and fosamprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc 2006; 38: 11381140.
  • 5
    Jain AB, Venkataramanan R, Eghtesad B et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl 2003; 9: 954960.
  • 6
    Kumar MS, Sierka DR, Damask AM et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 16221629.
  • 7
    Mazuecos A, Pascual J, Gomez E et al. Renal transplantation in HIV-infected patients in Spain. Nefrologia 2006; 26: 113120.
  • 8
    Drug Interactions; cytochrome P450 System, 2003. Accessed October 2, 2007.
  • 9
    Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44: 12731281.
  • 10
    Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129134.
  • 11
    Benet LZ, Wu C-Y, Hebert MF, Wacher VJ. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. J Control Rel 1996; 39: 139143.
  • 12
    Cummins CL, Salphati L, Ried MJ, Benet LZ. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 2003; 305: 306314.
  • 13
    Stock PG, Roland ME, Carlson L et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: A pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 14
    Christians U, Jacobsen W, Serkova N et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: Immunosuppressants. J Chromatogr B 2000; 748: 4153.
  • 15
    ThomsonPDR, ed. Physician's desk reference, 58th Ed. Montvale, NJ ; 2004: 1323, 2291, 3484.
  • 16
    Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int 1998; 54: 938944.
  • 17
    Christians U, Strom T, Zhang YL et al. Active drug transport of immunosuppressants: New insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006; 28: 3944.
  • 18
    Floren LC, Bekersky I, Benet LZ et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 4149.
  • 19
    Aarnoutse RE, Droste JA, Van Oosterhout JJ et al. Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol 2003; 55: 115125.
  • 20
    Nettles RE, Kieffer TL, Parsons T et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42: 11891196.